Patented biomarker for cardiac injury. 

cMyC Patents

International (PCT), European Union, UK, USA, Canada, China and Japan.

  • CMYBP-C and MLC2 as Diagnostic Marker of Cardiac Injury
  • Hybridoma Cell Lines (MY-C-CC0C2-259-1 A4) and use thereof for producing a monoclonal antibody against human cardiac myosin binding protein C (C-PROTEIN, MYBPC3, CMYBP-C OR MY-C)
  • Hybridoma Cell Lines (MY-C-CC0C2-235-3H8) and use thereof for producing a monoclonal antibody against human cardiac myosin binding protein C (C-PROTEIN, MYBPC3, CMYBP-C OR MY-C)

cMyC license rights for Lab and POC manufacturers

If you are interested in licensing the cMyC rights
for implementation on your Lab or Point of Care systems,
please contact us.

Antibodies, calibrants and samples can be made available for platform evaluation.
License